Investors / United States / Avoro Capital Advisors
Avoro Capital Advisors
Investor · New York, NY, United States · North America
Avoro Capital Advisors is a global life sciences investment firm focused on supporting emerging biotechnology companies. It provides companies with financial and intellectual support over the investment's lifecycle, using portfolio construction that may include tactical and fundamental hedges.
Invests inHealthcare & Biotech
In its own wordsbiotechnologylife sciencestherapeuticshealthcare
Your fit with Avoro Capital Advisors
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAvoro Capital Advisors lists 55 checked portfolio companies on its own site and is named in 2 funding rounds, 1 of them as lead. Its most frequent entry is Series B, 50% of the companies with a known first round. Its largest themes are Healthcare & Biotech (98%) and Media & Entertainment (2%). 78% of its companies are based in United States. It invests most often alongside Foresite Capital, RA Capital and Altamont Pharmaceutical Holdings.
Counts come from funding rounds that name Avoro Capital Advisors, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Avoro Capital Advisors' whole history. Rounds on record name 2 companies; its own site lists 55. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundAvoro Capital Advisors does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 50% |
| Growth | 50% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 1 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 86th | 55 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 59th | 4% of companies confirmed by a round |
| Sector focus | 97th | 98% in its largest sector |
| Reach | 84th | 6 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Foresite Capital | 11 |
| RA Capital | 9 |
| Altamont Pharmaceutical Holdings | 7 |
| Boxer Capital | 6 |
| Frazier Life Sciences | 5 |
| Versant Ventures | 5 |
| Atlas Venture | 4 |
| NEA | 4 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers4582%
- No longer answers00%
- Points to another company1018%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 98% | 15% |
| Media & Entertainment | 2% | 4% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Foresite Capital
Compare Avoro Capital Advisors head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Avoro Capital Advisors| Date | Company | Stage |
|---|---|---|
| 10 Jun 2026 | Series B Led | |
| 27 Oct 2025 | Series C+ |
Round details for Avoro Capital Advisors
Amounts, full round histories and every co-investor in Avoro Capital Advisors' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
55 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Portfolio page | ||||
| Adaptimmune is involved in cell therapies against cancer. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
Healthcare & Biotech | Portfolio page | |||
| Allogene Therapeutics develops cell therapies, including CAR T treatments, for cancer and autoimmune diseases. | Healthcare & Biotech | Portfolio page | ||
| Amarin is a global pharmaceutical company that has developed and is pursuing additional treatments to help address cardiovascular disease. | Healthcare & Biotech | Portfolio page | ||
| Amicus Therapeutics is a subsidiary of BioMarin Pharmaceutical Inc. focused on delivering medicines for people living with genetically defined conditions | Healthcare & Biotech | Portfolio page | ||
| Amylyx develops novel therapies for communities with high unmet needs, including diseases such as post-bariatric hypoglycemia, Wolfram syndrome, and amyotrophic lateral sclerosis. | Healthcare & Biotech | Portfolio page | ||
| Apellis develops life-changing medicines for patients with debilitating diseases | Healthcare & Biotech | Portfolio page | ||
| The company develops and provides immunology therapies and conducts clinical trials | Healthcare & Biotech | Portfolio page | ||
| Ascendis Pharma is a biopharmaceutical company that develops new therapies using its TransCon technology platform to improve treatment safety, efficacy, tolerability, and convenience. | Healthcare & Biotech | Portfolio page | ||
| Assembly Biosciences is developing novel therapies for serious viral and liver diseases. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Avidity Biosciences is developing RNA therapeutics for rare muscle diseases | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Corvus is a clinical-stage biopharmaceutical company developing novel therapies with the potential to significantly improve the treatment of immune diseases and cancer. | Healthcare & Biotech | Portfolio page | ||
| CRISPR Therapeutics is developing gene-based medicines for serious diseases | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| The company is advancing novel, small molecule therapeutic candidates designed to bring functional cures to serious genetic diseases with long-standing unmet need. | Healthcare & Biotech | Portfolio page | ||
| Ethyreal Bio is dedicated to improving the lives of people with Thyroid Eye Disease and Graves’ Disease | Healthcare & Biotech | Jun 2026Series B | Page + round |
About this data
site last read 5 Nov 2026- Site
- avorocapital.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 27 Oct 2025
- Companies checked
- 55
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Avoro Capital Advisors' profile as data
Pull Avoro Capital Advisors' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/avorocapital.com
# also
GET /v1/firms/avorocapital.com/portfolio
GET /v1/firms/avorocapital.com/coinvestors
GET /v1/firms/avorocapital.com/news